Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial.

摘要: Background: Misoprostol is known to be effective in stimulating intestinal transit both healthy individuals and patients with chronic constipation when evaluated short-term trials. The aim of this study was determine the utility misoprostol long-term management refractory constipation. Methods: Eighteen were offered (600–2400 μg/day) as adjunctive therapy an open-ended, non-blinded trial. All encouraged continue drug for a minimum 4 weeks, after which time effect on bowel movement patterns continued use those who demonstrated clinical benefit. Results: Six withdrew prior 4 weeks because side-effects. In 12 treatment at mean interval between frequency had decreased from baseline 11.25 4.8 days (P=0.0004). Eight treatment, sustained response seen six. subset (n=4) single-dose (400 μg) compared controls (n=5) post-prandial segmental colonic motility. Misoprostol augmented motility meal throughout colon, significantly greater left versus right segments (P < 0.05). Conclusions: Misoprostol can part medical constipation, but side-effects are observed higher doses limiting factor. Part misoprostol's action may mediated through augmentation motility, particularly colon.